Key facts
- This page summarizes Carl L. Gordon's Form 4 filing for Keros Therapeutics, Inc. (KROS).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Dec 2025, 16:27.
Carl L. Gordon - 21 Nov 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)
- Reporting relationship
- Director
- Issuer ticker
- KROS
- Reported as of
- 21 Nov 2025
- Net transaction value
- -$3,807,766
- SEC form
- 4
- Accepted by SEC
- 18 Dec 2025, 16:27:15 UTC
- Prior SEC filing
- 06 Jun 2025
- Next SEC filing
- 05 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Carl L. Gordon filed Form 4 for Keros Therapeutics, Inc. (KROS) on 18 Dec 2025.
Change
- Previous filing in this sequence was filed on 06 Jun 2025.
- Current net transaction value: -$3,807,766.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001282930
Primary reporting owner
GORDON CARL L
- Relationship
- Director
- Address
- C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON
- Signature
- /s/ Carl L. Gordon
- Signature date
- 18 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KROS
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $2,486,012
- Shares
- -140,057
- Change %
- -16%
- Price
- $17.75
- Shares after
- 759,155
- Date
- 21 Nov 2025
- Ownership
- See footnotes
- Footnotes
- F1, F2, F4
KROS
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $1,321,754
- Shares
- -74,465
- Change %
- -62%
- Price
- $17.75
- Shares after
- 45,057
- Date
- 21 Nov 2025
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Disposed of in connection with the Issuer's completion of a cash tender offer.
Footnote F2
These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
Footnote F3
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
Footnote F4
Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.